20-F: NewGenIvf Group Limited Files 20-F Annual Report, Cites Going Concern Uncertainty

NewGenIvf Group Limited's 20-F filing reveals a net loss for 2024 and concerns about its ability to continue as a going concern due to limited cash reserves.

Summary

• NewGenIvf Group Limited filed its 20-F annual report, highlighting its business in fertility treatments and surrogacy services.
• The company reported a net loss of US$(474,101) for the year ended December 31, 2024, a decrease from the net income of US$108,418 in 2023.
• Revenue increased slightly from US$5,136,153 in 2023 to US$5,433,375 in 2024, with IVF treatment services accounting for 100% of the revenue in 2024.
• The report expresses substantial doubt about the company's ability to continue as a going concern, with cash and cash equivalents standing at approximately US$457,740 as of December 31, 2024.
• The company is pursuing fundraising projects and has access to an equity line of credit facility of up to US$100 million, of which approximately US$7.1 million has been drawn and become equity to date.
• A reverse stock split of 1-for-20 was effected on February 11, 2025, to regain compliance with Nasdaq listing requirements.
• The company's securities were transferred to the Nasdaq Capital Market on February 28, 2025.
• NewGenIvf operates three clinics: one in Thailand, one in Cambodia, and one in Kyrgyzstan.
• The company acquired MicroSort technology from Genetics & IVF Institute, Inc. in February 2025.
• The company terminated a proposed reverse merger with European Wellness Investment Holdings Limited (EWIHL) on March 31, 2025.
• The company entered into a new Securities Purchase Agreement with JAK Opportunities VI LLC on April 1, 2025, for potential additional financing.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased, the net loss and going concern uncertainty weigh heavily on the sentiment. The potential for future capital raises offers some hope, but the overall outlook is cautious.

Positives

• Revenue increased from US$5,136,153 in 2023 to US$5,433,375 in 2024.
• The company has access to an equity line of credit facility of up to US$100 million.
• NewGenIvf acquired MicroSort technology, potentially enhancing its service offerings.
• The company regained compliance with Nasdaq listing requirements after implementing a reverse stock split and transferring to the Nasdaq Capital Market.

Negatives

• The company reported a net loss of US$(474,101) for 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to limited cash reserves.
• The company's disclosure controls and procedures were deemed ineffective as of December 31, 2024.
• Surrogacy and ancillary caring services revenue decreased by 100% from 2023 to 2024 due to reorganization in Kyrgyzstan.

Risks

• The company may not be able to continue operating as a going concern.
• The fertility market is competitive, and NewGenIvf faces significant competition.
• The company has a limited operating history with its current platform of solutions.
• Failure to timely file reports with the SEC could result in enforcement action and delisting from Nasdaq.
• The company's business depends on its ability to maintain its existing client demographics.
• Fluctuations in exchange rates could have a material and adverse effect on the company's results of operations.
• Sales of a substantial number of the company's securities in the public market could cause the market price of its Class A Ordinary Shares to decrease significantly.
• Substantially all of NewGenIvfs assets and operations are located in Thailand, Cambodia and Kyrgyzstan and they are subject to economic, legal and regulatory uncertainties in such countries.
• Failure to comply with the terms of future financing arrangements could result in default, which could have an adverse effect on NewGenIvfs cash flow and liquidity.
• The defects in certain leased property interests and failure to register certain lease agreements may materially and adversely affect NewGenIvfs business, financial condition, results of operations, and prospects.
• NewGenIvf currently has no insurance coverage for its operations.
• NewGenIvf may not be successful in adapting to technological developments, which may affect its business and results of operations.
• If its computer systems, or those of its providers, specialty pharmacies or other downstream vendors lag, fail or suffer security breaches, NewGenIvf may incur a material disruption of its services, which could materially impact its business and the results of operations.
• NewGenIvf operates in a highly regulated industry and must comply with a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits applicable to NewGenIvfs business may have a material and adverse impact on NewGenIvfs business, financial condition, and results of operations
• NewGenIvfs business depends on its ability to maintain its network of high-quality fertility specialists and other healthcare providers. If NewGenIvf is unable to do so, its future growth would be limited and its business, financial condition and results of operations would be harmed.
• The medical facilities and professionals in NewGenIvfs network could become the subject of litigation, allegations and other claims, and NewGenIvf is not insured against these liabilities.
• The assisted reproductive medical facilities in NewGenIvfs network have limited control over the quality of the pharmaceuticals, medical equipment, medical consumables and other supplies used in its operations, and cannot guarantee that the products in use are not defective or counterfeit. NewGenIvf also has no control over independent sub-contractors and cannot guarantee the services thereof.
• NewGenIvf has engaged in transactions with related parties, and such transactions present potential conflicts of interest that could have an adverse effect on its business and results of operations.
• NewGenIvf may be subject to claims and allegations relating to intellectual property and other causes.
• Certain data and information in this prospectus relied on by NewGenIvf were obtained from third-party data and polls. These metrics were not independently verified by NewGenIvf and may not be accurate.
• Legal or regulatory restriction, government regulation, industry standards and other requirements create risks and challenges with respect to NewGenIvfs compliance efforts and its business strategies and could adversely impact NewGenIvfs business and limited the growth of NewGenIvfs operations.
• Significant tariffs or other restrictions imposed on imports by the U.S. and related countermeasures taken by impacted countries could have a material adverse effect on our operations and financial results.
• Any litigation against NewGenIvf could be costly and time-consuming to defend and could harm its business, financial condition and results of operations.
• Acquisitions, strategic investments, partnerships, or alliances could be difficult to identify, pose integration challenges, divert the attention of management, disrupt NewGenIvfs business, dilute stockholder value, and adversely affect its business, financial condition and results of operations.
• Changes in NewGenIvfs effective tax rate or tax liability may have an adverse effect on its results of operations.
• NewGenIvfs reported financial results may be adversely affected by changes in accounting principles generally accepted in the U.S.
• If NewGenIvfs estimates or judgments relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely affected.
• NewGenIvf is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it to criminal or civil liability and harm its business, financial condition and results of operations.

Future Outlook

The company plans to offer broad fertility services, invest in laboratories and facilities, increase brand awareness, and expand service reach through acquisitions and partnerships.

Industry Context

The company operates in the assisted reproductive services (ARS) market in the Asia Pacific region, which is expected to grow due to increasing infertility rates and demand for fertility treatments.

Comparison to Industry Standards

• The document mentions that the average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding medication).
• The document mentions that NewGenIvf mainly competes with mid-level private clinics and hospitals, which have improved and developed their services and equipment over the years.
• The document mentions that foreign medical companies may also enter the markets where NewGenIvf operates and may be well-placed to compete with NewGenIvf due to their larger network size, reputation as global players and access to more advanced technology and financial resources.

Management Changes

Corporate Governance

Related Party Transactions

• Historically, certain amount of cash provided by operating activities was given to Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong, resulting in amount due from them.
• In addition, NewGenIvf also recorded remuneration to its directors, Mr. Siu and Ms. Fong.
• On April 3, 2024, the Company issued an aggregate principal amount of promissory notes of $2,000,000 to JAK OPPORTUNITIES VI LLC (JAK).
• On August 7, 2024, the Company entered into a Securities Purchase Agreement (Securities Purchase Agreement) with JAK, pursuant to which, amongst other things: (i) the Company agreed to sell, at an initial closing (and such initial closing, the Initial Closing), (a) a senior convertible note (the Initial Note) in the aggregate original principal amount not exceeding $1,100,000, convertible into Class A Ordinary Shares pursuant to its terms, (b) a warrant to purchase 1,325,301 Class A Ordinary Shares (such warrant, the Series A Warrant), and (c) a warrant to purchase 180,722 Class A Ordinary Shares (the Series B Warrant); and (ii) the Company may require JAK (or JAK may require the Company, as applicable) to participate in the sale of (a) one or more additional convertible notes (which aggregate original principal amount for all additional convertible notes shall not exceed $9,500,000) (the Additional Notes) and (b) related Warrants.
• Additionally, in connection with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with JAK, pursuant to which the Company exchanged the Existing Notes by issuing, among other things, (i) senior convertible notes in the aggregate principal amount of $2,700,000 (the Exchange Notes, and, together with the Initial Note and the Additional Notes, the Notes) and (b) a series of warrants to initially acquire up to a certain number of Ordinary Shares to JAK.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers may experience changes in service offerings or pricing due to the company's financial situation.
• Suppliers and creditors face increased risk of delayed or reduced payments.

Next Steps

• The company intends to implement measures to address the identified material weakness in its internal control over financial reporting.
• The company plans to offer broad fertility services, invest in laboratories and facilities, increase brand awareness, and expand service reach through acquisitions and partnerships.

Key Dates

Keywords

NewGenIvf, fertility, IVF, surrogacy, financial results, 20-F, annual report, going concern, reverse stock split, MicroSort, Nasdaq, financial statements